Wylie David Hosmer, MD | Hartford ...

Dr. Wylie Hosmer, MD

Claim this profile

Hartford Hospital

Studies Lung Cancer
Studies Colorectal Cancer
6 reported clinical trials
26 drugs studied

Area of expertise

1

Lung Cancer

Wylie Hosmer, MD has run 3 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III
2

Colorectal Cancer

Wylie Hosmer, MD has run 2 trials for Colorectal Cancer. Some of their research focus areas include:

Stage III
Stage IV
KRAS positive

Affiliated Hospitals

Image of trial facility.

Hartford Hospital

Image of trial facility.

The Hospital Of Central Connecticut

Clinical Trials Wylie Hosmer, MD is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Recruiting

2 awards

Phase 3

28 criteria

Image of trial facility.

Targeted Therapy

for Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Recruiting

1 award

Phase 2

9 criteria

More about Wylie Hosmer, MD

Clinical Trial Related

11 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Wylie Hosmer, MD has experience with

  • Crizotinib
  • Pembrolizumab
  • Atezolizumab And PHESGO
  • Futibatinib
  • Sunitinib
  • Regorafenib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Wylie Hosmer, MD specialize in?

Is Wylie Hosmer, MD currently recruiting for clinical trials?

Are there any treatments that Wylie Hosmer, MD has studied deeply?

What is the best way to schedule an appointment with Wylie Hosmer, MD?

What is the office address of Wylie Hosmer, MD?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security